We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.32 | -0.80% | 39.69 | 40.005 | 39.63 | 39.97 | 1,064,030 | 16:17:27 |
From Jul 2021 to Jul 2024
By Cecilia Butini
GlaxoSmithKline PLC said Tuesday that it has appointed six directors to the board of Haleon, the new company set to be formed through the demerger of Glaxo's consumer healthcare unit.
The British pharma giant said the appointments include two Glaxo nonexecutive directors and three new external members. Haleon's chief financial officer designate Tobias Hestler is expected to become executive director together with Chief Executive Officer Designate Brian McNamara, Glaxo said.
Mr. Hestler is exepected to be appointed as director prior to the company's demerger, which is expected in July 2022, while all the other appointments are to become effective starting from the demerger, Glaxo said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 15, 2022 06:32 ET (10:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
